|
On Monday, equities plunged in their worst session since September amid a surge in Covid-19 cases across the country.
|
|
 Gold futures early Tuesday hold steady as indications for a tepid rebound in equities, following Monday's stock-market rout due to rising COVID-19 cases, cause some pause in bullion buying.
|
|
 Shares of Cummins Inc. surged 4.2% toward a record high in premarket trading Tuesday, after the diesel, natural gas and electric engines maker reported third-quarter profit and sales that fell, but beat expectations, and provided an upbeat outlook. Net income declined to $501 million, or $3.36 a share, from $622 million, or $3.97 a share, in the year-ago period. The FactSet consensus for earnings per share was $2.42. Revenue declined 11.3% to $5.12 billion, but beat the FactSet consensus of $4.51 billion. Engine sales fell 13% to $2.1 billion to beat expectations of $1.71 billion; components sales were down 14% to $1.7 billion but topped expectations of $1.24 billion; and power systems sales declined 13% to $981 million, but topped forecasts of $794.5 million; while distribution sales slid 14% to $1.7 billion, just shy of expectations of $1.75 billion. The company said it expects fourth-quarter sales to be "similar" to third-quarter levels, which would be above the current FactSet consensus of $4.77 billion. Cummins said that on Oct. 1, it ended the temporary salary reductions that were implemented in April. The stock has rallied 15.6% over the past three months through Monday, while the S&P 500 has gained 5.0%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
|
|
Equities fall again as worries grow about the region's economic recovery
|
|
Shares of Pfizer Inc. were up 0.1% in premarket trading on Tuesday after the drug maker missed sales expectations for the quarter. Pfizer had earnings of $2.2 billion, or 39 cents per share, in the third quarter of 2020, down from $7.7 billion, or $1.36 per share, in the same quarter a year ago. It had adjusted earnings per share of 72 cents for the quarter, against a FactSet consensus of 71 cents. The drug company's revenue fell 4% to $12.1 billion for the quarter, compared with $12.7 billion in the same quarter a year ago. The FactSet consensus was $12.3 billion. The company attributed an estimated unfavorable impact of $500 million for the quarter to the COVID-19 pandemic, citing lower demand for anti-infective products used in surgeries in China and disruptions in traditional prescribing patterns in the U.S. as people avoided going to to the doctor, including a 19% drop in sales of its smoking-cessation drug Chantix. The impact was offset to some degree by "strong performance" of its heart drugs, Vyndaqel and Vyndamax, and its biosimilars business. It did not disclose any additional details about its work to develop a COVID-19 vaccine with BioNTech . However, it did note that the Phase 2/3 clinical trial for the vaccine candidate had enrolled 42,000 participants as of Monday, and about 85% of the participants have received their second and final dose of the experimental vaccine. Pfizer adjusted its 2020 guidance for adjusted earning share to $2.88 to $2.93, from $2.85 to $2.95. Pfizer's stock is down 3.2% for the year, compared with the S&P 500 , which has gained 5.2%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
|
|
SHG earnings call for the period ending September 30, 2020.
|
RELATED ARTICLES | | |
|
The global tally for confirmed cases of the coronavirus that causes COVID-19 climbed above 43.5 million on Tuesday, according to data aggregated by Johns Hopkins University, while the death toll rose to 1.16 million. The U.S. has the highest case total at 8.7 million and deaths at 225,735. The U.S. has averaged 71,000 new cases a day in the last week, it's highest for a 7-day period since the start of the outbreak, the New York Times reported.
Brazil has the second highest death toll at 157,397 and is third by cases at 5.4 million. India is second in cases with 7.9 million, and third in deaths at 119,502. Mexico has the fourth highest death toll at 89,171 and ninth highest case tally at 895,326. The U.K has 45,088 deaths, the highest in Europe and fifth highest in the world, and 897,740 cases.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
|
RELATED ARTICLES | | |
|
Consumers won't stop buying these companies' products -- even at the worst of times.
|
|
3M reported third-quarter results that beat analyst expectations on the back of strong personal-safety and health equipment sales.
|
|
Which one of these biotech stocks has a better chance to provide market-beating gains?
|
RELATED ARTICLES | | |
|
The manufacturer's profit fell as expenses grew and demand for products serving industries affected by the Covid-19 pandemic continued to decline.
|
RELATED ARTICLES | | |
|
 The upbeat results showed Merck was on a recovery path after its revenue took a hit at the height of the pandemic, nudging the company's shares about 2% higher in premarket trading. Sales of Keytruda, which is an approved treatment for cancers including non-small-cell lung cancer, rose 21% to $3.7 billion, above analysts estimates of $3.66 billion, according to six analysts polled by Refinitiv. Merck said it now expects full-year adjusted profit of between $5.91 and $6.01 per share, compared with its prior forecast of between $5.63 to $5.78 per share.
|
|
Everyone's abuzz about the upcoming election, but the boring truth is: it might not mean much for the market.
|
RELATED ARTICLES | | |
|
Nearly 70 percent of organizations that have furloughed or laid off their employees during the novel coronavirus pandemic plan to back-fill the roles that were eliminated with other employees taking over.
|
|
2020-10-27 0001213900-20-033391 32 KB
|
RELATED ARTICLES | | | | |
|
U.S. stock futures pared gains Tuesday, one day after the Dow led a huge down day on Wall Street.
|
RELATED ARTICLES | | |
|
AMD in $35 Billion All-Stock Acquisition of Xilinx AnandTechAMD to buy chip peer Xilinx for $35 billion in data center push CNBCAdvanced Micro to buy Xilinx for $35 billion in stock CNBC TelevisionAMD to acquire Xilinx in all-stock deal valued at $35 billion MarketWatchAMD is buying a rival chipmaker for $35 billion CNN
|
RELATED ARTICLES | | |
|
Ant Group will close its Hong Kong institutional book building process a day earlier than expected due to strong demand for its record initial public offering (IPO),
|
RELATED ARTICLES | | |
|
The Chinese fintech giant, currently the world's most valuable startup, is about to make history with record-breaking IPOs in Hong Kong and Shanghai. How did it become so big?
|
RELATED ARTICLES | | |
|
 It's down to the wire. The U.S. Presidential elections are only a week away, and with the polls showing Biden has an edge over President Trump, investors are preparing.Oppenheimer's Chief Investment Strategist John Stoltzfus points out that last week, stocks churned as investors rebalanced their portfolios, rotating and adding additional exposure to value stocks "while others took profits in growth names that had previously run-up substantially ahead of what could be higher capital gains and other taxes next year," in the event that the Democrats come out on top.Highlighting that the expectation of an effective COVID-19 vaccine is behind the broadening of investor appetite for equities, Stoltzfus argues this renewed appetite " improves the attractiveness of value stocks."Going forward, the strategist notes the Federal Reserve's efforts "underscore the case for the economy's recovery and the equity markets' resilience and potential from here." Although a "blue wave" is seen as a potential risk, Stoltzfus thinks this outcome is very unlikely, and that continued split control should alleviate market worries.Taking Stoltzfus' outlook into consideration, our attention turned to three stocks Oppenheimer analysts believe can surge by at least 70% in the year ahead. Running the tickers through TipRanks' database, we found out that each boasts a "Strong Buy" consensus rating from the broader analyst community.Chromadex (CDXC)Focused on improving the way people age, Chromadex operates as a science-based integrated
|
|
2020-10-27 0001558370-20-011768 8 MB
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits
|
RELATED ARTICLES | | | | |
|
If you sell stocks, mutual funds or other capital assets that you held for at least one year, any gain from the sale is taxed at either a 0%, 15% or 20% rate. Those tax rates for long-term capital gains are typically much lower than the ordinary tax rates you'd otherwise pay, which can be as high as 37%.
SEE MORE IRS Releases Income Tax Brackets for 2021
However, which one of those capital gains rates - 0%, 15% or 20% - applies to you depends on your taxable income. The higher your income, the higher the rate.
The taxable income thresholds for the capital gains tax rates are adjusted each year for inflation. The IRS has already released the 2021 thresholds (see table below), so you can start planning for 2021 capital asset sales now.
2021 Capital Gains Tax Rate Thresholds
Capital Gains
Tax Rate
Taxable Income
(Single)
Taxable Income
(Married Filing Separate)
Taxable Income
(Head of Household)
Taxable Income
(Married Filing Jointly)
0%
Up to $40,400
Up to $40,400
Up to $54,100
Up to $80,800
15%
$40,401 to $445,850
$40,401 to $250,800
$54,101 to $473,750
$80,801 to $501,600
20%
Over $445,850
Over $250,800
Over $473,750
Over $501,600
Tax on Net Investment Income
There's an additional 3.8% surtax on net investment income (NII)
|
RELATED ARTICLES | | |
|
The U.S. case tally for the coronavirus illness COVID-19 climbed above 8.7 million on Tuesday, with more than 20 states counting record numbers of new infections, as more business curfews were announced to combat the spread.
|
|
Shares of the cloud-based communications specialist have tripled so far this year.
|
|
The stocks making the biggest moves in premarket trading include Xilinx, Merck, Caterpillar, 3M, and more.
|
|
‘I'm a 36-year-old man with no plans on having children, and I'd like to be able to use this very small amount to pursue one of my passions in life.'
|
|
Black man shot dead by police in Philadelphia, sparking heated protests NBC NewsPhiladelphia police shooting of armed Black man sparks violent clashes, at least 30 cops injured: reports Fox NewsWalter Wallace shooting: Man reportedly armed with knife shot, killed by police in Philadelphia 6abc PhiladelphiaProtesters Gather Outside Police Precinct Hours After Officers Fatally Shoot Man Armed With Knife In West Philadelphia CBS Philly
|
|
Boston Herald endorses Donald Trump for president WCVB BostonTrump eyes hosting election night party at his DC hotel The Associated PressUS election 2020: President Trump casts his vote - BBC News BBC NewsDonald Trump Jr. holds MAGA rally in Washington Township on Monday WDIV ClickOnDetroitThe Plot to Kidnap Me The Atlantic
|
|
Protests grip Philadelphia, leaving officers injured and stores damaged, after police kill a Black man The Washington PostViolent clashes break out in Philadelphia after police fatally shoot man with knife: report Fox NewsWalter Wallace shooting: Man reportedly armed with knife shot, killed by police in Philadelphia 6abc PhiladelphiaPhiladelphia police shoot and kill man after yelling at him to drop knife TribLIVEMan Dies After Police-Involved Shooting In West Philadelphia CBS Philly
|
|
Despite Trump-Modi Friendship, Survey Says Indian Americans Back Biden NPRKayleigh McEnany once praised Biden as a 'man of the people' who resonates with "middle class" over 'tycoon' Trump CNNYahoo News/YouGov poll: With one week left, Biden's lead over Trump grows to 12 points — his biggest yet Yahoo NewsThe New York Post endorses President Donald J. Trump for re-election New York Post
|
|
 European stocks struggle as investors juggle earnings with COVID-19 resurgence
|
RELATED ARTICLES | | |
|
 The Wayfair Black Friday 2020 preview event is here with some of the biggest early Black Friday deals on furniture and décor you won't want to miss—details.
|
|
 COVID-19 immunity may only last a few months after infection, study indicates
|
RELATED ARTICLES | | |
|
 Yahoo Finance's Alexis Christoforous, Brian Sozzi, and Jared Blikre discuss AMD buying rival chipmaker Xilinx in an all-stock deal.
|
|
 For a day that marked Tesla's (TSLA) fifth straight quarter of reporting positive profits, last week's 0.7% increase in the share price of Tesla stock seemed somewhat underwhelming.Reporting earnings Wednesday night, Tesla closed trading Thursday up only modestly, and really, only barely outperforming the S&P 500's overall 0.5% move. Tesla called Q3 its "best quarter in history," with pro forma earnings coming in 36% ahead of expectations at $0.76 per share, sales of $8.8 billion about 6% better than predicted, and free cash flowing strongly -- $1.9 billion over the past 12 months.Tesla told investors Wednesday that it remains on target to produce and deliver half a million electric cars this year, despite the fact that "this goal has become more difficult" to achieve in the face of Covid-19. Cybertruck deliveries are expected to begin late next year. Even Tesla's "energy" business -- solar roofs and solar storage -- looks "poised for strong growth," said the company.Much of Wall Street applauded the news, with R.W. Baird and JMP Securities both upgrading Tesla shares to "outperform" and Piper Sandler calling Tesla a "must-own" stock, and as both Oppenheimer and RBC Capital raised price targets on the shares. One analyst, however, stood out from the crowd for his continued pessimism on Tesla:Gordon Johnson of GLJ Research says Tesla is still a "sell."Urging investors not to forget the forest for the trees, Johnson reminds Elon Musk fans that Tesla continues to rely heavily upon
|
|
The findings of the study could deal a blow to those pushing for so-called herd immunity.
|
|
The Chinese fintech firm is set to break I.P.O. records.
|
|
The Covid-19 pandemic weighed down sales for some drugs in the latest quarter as the company's candidate vaccine for the virus that has caused the public-health crisis continues in a large late-stage trial.
|
|
Private equity newcomer Teleo Capital has acquired Rand McNelly. The fleet management and asset tracking solution provider now plans to accelerate the development of its technology. The details about the deal were not disclosed, DC velocity reported. Teleo named its operating partner Joseph Roark as chairman of Rand McNally as following the deal. "We are […]
|
|
 Pfizer said in a presentation that the independent monitor which will determine whether or not the trial has been successful has not conducted any interim efficacy analyses yet. Chief Executive Albert Bourla has previously said the company could release data on whether or not the vaccine works as early as this month. U.S. President Donald Trump had said a vaccine could be available before the Nov. 3 election, but in recent weeks his administration has emphasized that one will be ready this year.
|
RELATED ARTICLES | | |
|
Social Security may be cut in the future -- but the wrong moves on your part could shrink your benefits even more.
|
RELATED ARTICLES | | |
|
 Is Chipotle Mexican Grill, Inc. (NYSE:CMG) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise […]
|
|
Shares of Novavax Inc. gained 2.9% in trading on Tuesday after the company said it expects to launch a Phase 3 trial for its COVID-19 vaccine candidate in Mexico and the U.S. by the end of next month. It already started a late-stage trial for its vaccine in the U.K. in September. Novavax has published some data for its experimental COVID-19 vaccine from its Phase 1 clinical trial, in September in the New England Journal of Medicine. It said Tuesday it plans to present new reactogenicity data from the Phase 2 trial on Friday, during an advisory committee on immunization practices meeting convened by the Centers for Disease Control and Prevention. Novavax's stock has soared 2,180.1% so far this year, compared with the S&P 500 , which is up 5.2%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
|
RELATED ARTICLES | | |
|
 OneMain Holdings raised its quarterly dividend by 36% to $0.45 per share after the financial services company's 3Q profit exceeded analysts' estimates. The dividend will be paid on Nov. 17 to shareholders on record as of Nov. 9. OneMain shares are up 1.5% in the pre-market session on Tuesday.OneMain's (OMF) 3Q EPS increased 2.2% year-on-year to $1.86 and came ahead of the Street consensus of $1.22. However, 3Q revenues fell 4.3% year-on-year to $935 million, missing analysts' expectations by $3.42 million.OneMain said that its Consumer and Insurance (C&I) segment's adjusted earnings rose to $2.19 per share in 3Q, up from the $1.77 per share in the prior-year quarter. Moreover, the C&I's provision for finance receivable losses of $232 million in 3Q declined from the year-ago quarter of $277 million, primarily due to the impact of lower delinquencies in the portfolio.OneMain's CEO Doug Shulman said that "Our third quarter financial results reflected continued strength across the core drivers of our business, as well as our focused efforts to support customers during this period of uncertainty." He added that "Advanced data and analytics are driving our sophisticated underwriting and continued innovation, enabling OneMain to continue to enhance and strategically evolve our business while driving strong returns for all stakeholders." (See OMF stock analysis on TipRanks).Following the results, Northland Securities analyst Michael Grondahl maintained a Buy rating and a price target of $40 (6.6% upside
|
|
 Cristan Blackman's Empirical Capital Partners is a Tennessee-based hedge fund founded in 2000 that takes a small number of concentrated positions in high-quality companies, with the fund investing the bulk of its assets in those companies which it sees as having the greatest potential for near-term gains. The fund managed a 13F portfolio containing $70.1 […]
|
RELATED ARTICLES | | | | | | | | | | | | | | | | | | | |
 Home Depot's Black Friday 2020 sale runs Nov. 6 through Dec. 2 amid the COVID-19 pandemic. The holiday deals will be available while supplies last.
|
|
Payments group poised to top Saudi Aramco's haul after it priced in Shanghai and Hong Kong
|
|
It's never too early to start thinking about your next tax return. For most Americans, that'll be your federal tax return for the 2020 tax year — which, by the way, will be due on April 15, 2021 (or October 15, 2021, if extended). The 2020 tax rates themselves are the same as the rates in effect for the 2019 tax year: 10%, 12%, 22%, 24%, 32%, 35% and 37%. However, as they are every year, the 2020 tax brackets were adjusted to account for inflation. That means you could wind up in a different tax bracket when you file your 2020 return than the bracket you were in before - which also means you'll be paying a different tax rate on some of your income.
SEE MORE Tax Changes and Key Amounts for the 2020 Tax Year
The tax bracket ranges also differ depending on your filing status. For example, the 22% tax bracket for the 2020 tax year goes from $40,126 to $85,525 for single taxpayers, but it starts at $53,701 and ends at $85,500 for head-of-household filers.
The difference between bracket ranges sometimes creates a "marriage penalty." This tax-law twist makes certain married couples filing a joint return — typically, where the spouses' incomes are similar — pay more tax than they would if they were single. The penalty is triggered when, for any given rate, the minimum taxable income for the joint filers' tax bracket is less than twice the minimum amount for the single filers' bracket. Before the 2017 tax reform law, this happened in the four highest tax brackets. But now, as you can see in the tables below, only the top tax bracket contains the marriage penalty trap. As a result, only couples with a combined taxable income over $622,050 are at risk when filing thei
|
|
'Critical juncture': Little moves Idaho back to Stage 3 amid sustained coronavirus surge East Idaho NewsIdaho governor orders return to some COVID-19 gathering restrictions as infections surge oregonlive.comIdaho moves back to Stage 3 amid healthcare capacity constraints statewide East Idaho NewsIdaho moves back to Stage 3, but with no mask mandate or enforcement, will it do any good? Idaho Statesman
|
|
Dow Jones Futures: Stock Market Rally Struggles As Coronavirus Cases Soar; Dexcom, Twilio Are Key Movers Late Investor's Business DailyDow drops 650 points as S&P 500, Nasdaq post worst day since September Fox BusinessAsian shares slip after Wall St's worst day in a month KTAR.comDow Slumps as Record Surge in Infection Triggers Bloodbath Investing.comWall Street tumbles as virus cases soar Reuters
|
|
Fact check: At Pennsylvania rally, Trump makes four false claims about voting in the state CNNTrump, Biden Campaign In Battleground Pennsylvania As Election Day Nears | NBC Nightly News NBC NewsRoad to 270: Biden leading in these battleground states CNNTrump is cruising for a bruising | TheHill The HillThe New York Post endorses President Donald J. Trump for re-election New York Post
|
|
32 years since their last championship, Dodgers are a single win away from an elusive 7th World Series title KTLA Los AngelesWhat year is it?! Manuel Margot tries wildly aggressive straight steal of home Yahoo Sports2020 World Series: Dodgers Fans' Opinions of Joe Buck Dodgers NationOutside The Confines: Let's talk
|
|
 Mark McMeans' Brasada Capital Management is a Houston-based long/short equity hedge fund founded in 2008. The fund takes a conservative approach to its investments, including using hedging and risk management strategies to achieve its desired risk-adjusted returns. The fund's assets under management more than doubled between early-2017 and early-2018, and topped $542 million in the […]
|
|
 Eli Lilly and Company (NYSE: LLY) said Monday that a trial of its antibody treatment for use in hospitalized COVID-19 patients has come to an end as the treatment is unlikely to help such patients. What Happened: The one of its kind study -- conducted by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health -- was evaluating the efficacy of bamlanivimab, according to a statement issued by the company.Eli Lilly said that trial data has led to the recommendation that the treatment is unlikely to help hospitalized COVID-19 patients recover from an advanced stage of the disease.Other studies investigating bamlanivimab will continue, including an NIH-sponsored study evaluating the efficacy of the treatment in mild-to-moderate COVID-19 cases and the company's own Phase 2 trial in people recently diagnosed with COVID-19 in a non-hospitalized setting.Why It Matters: The Indianapolis, Indiana-based drug giant said it has submitted for an emergency use authorization for bamlanivimab based on its own Phase 2 trial results.This month, the drugmaker halted the Phase 3 trial of its antibody treatment due to a "potential safety concern." It was reported earlier that the Eli Lilly plant being readied to make the antibody treatment for COVID-19 was found to have serious quality control problems by the United States Food and Drug Administration.President Donald Trump was administered a similar antibody treatment from Regeneron Pharmaceutic
|
RELATED ARTICLES | | | | | |
How should social media deal with controversial subjects or false information?
|
|
With the coronavirus pandemic still raging globally, China will be the only major economy in the world to post positive growth this year.
|
Manage Folders
Manage Ticker/Headlines
Choose from News Feed Directory
Add Your Own Feed
Create Feed Using Search Terms
|
Choose from News Feed Directory
Add Your Own Feed
Create Feed Using Search Terms
|
|
Private Label